Lifestyle changes and the risk of developing endometrial and ovarian cancers: Opportunities for prevention and management

International Journal of Women's Health

Volumn 8, Issue , 2016, Pages 151-167

  Beavis, Anna L ^a   Smith, Anna Jo Bodurtha ^b   Fader, Amanda Nickles ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Endometrial cancer; Gynecologic cancer; Lifestyle; Obesity; Ovarian cancer; Prevention

Indexed keywords

METFORMIN; NONSTEROID ANTIINFLAMMATORY AGENT;

ALCOHOL CONSUMPTION; BARIATRIC SURGERY; BREAST FEEDING; CANCER MORTALITY; CANCER PREVENTION; CANCER RECURRENCE; CANCER RISK; CHEMOPROPHYLAXIS; ENDOMETRIUM CANCER; HORMONE SUBSTITUTION; HUMAN; LIFESTYLE MODIFICATION; MEDITERRANEAN DIET; OBESITY; ORAL CONTRACEPTIVE USE; OVARY CANCER; PHYSICAL ACTIVITY; QUALITY OF LIFE; REVIEW; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; SMOKING; WEIGHT REDUCTION;

EID: 84974806064     PISSN: None     EISSN: 11791411     Source Type: Journal    
DOI: 10.2147/IJWH.S88367     Document Type: Review

References (156)

1. Stevens G. Global health risks: mortality and burden of disease attributable to selected major risks. Bull World Health Organ. 2009;87:646–646.
2. Carter BD, Abnet CC, Feskanich D, et al. Smoking and mortality – beyond established causes. N Engl J Med. 2015;372(7):631–640.
3. Colditz GA, Atwood KA, Emmons K, et al. Harvard report on cancer prevention volume 4: Harvard cancer risk index. Cancer Causes Control. 2000;11(6):477–488.
4. De Pergola G, Silvestris F. Obesity as a major risk factor for cancer. J Obes. 2013;2013:291546.
5. Ryan AM, Cushen S, Schellekens H, et al. Poor awareness of risk factors for cancer in Irish adults: results of a large survey and review of the literature. Oncologist. 2015;20(4):372–378.
6. Kelly T, Yang W, Chen C-S, Reynolds K, He J. Global burden of obesity in 2005 and projections to 2030. Int J Obes (Lond). 2008;32(9):1431–1437.
7. Ward KK, Shah NR, Saenz CC, McHale MT, Alvarez EA, Plaxe SC. Cardiovascular disease is the leading cause of death among endometrial cancer patients. Gynecol Oncol. 2012;126(2):176–179.
8. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med. 2003;348(17):1625–1638.
9. Jayson GC, Kohn EC, Kitchener HC, Ledermann JA. Ovarian cancer. Lancet. 2014;384(9951):1376–1388.
10. Toledo E, Salas-Salvadó J, Donat-Vargas C, et al. Mediterranean diet and invasive breast cancer risk among women at high cardiovascular risk in the PREDIMED Trial. JAMA Intern Med. 2015;175(11):1752–1760.
11. Sutcliffe P, Connock M, Gurung T, et al. Aspirin for prophylactic use in the primary prevention of cardiovascular disease and cancer: a systematic review and overview of reviews. Health Technol Assess. 2013;17(43):1–253.
12. Kushi LH, Doyle C, McCullough M, et al. American Cancer Society Guidelines on nutrition and physical activity for cancer prevention: reducing the risk of cancer with healthy food choices and physical activity. CA Cancer J Clin. 2012;62(1):30–67.
13. Rock CL, Doyle C, Demark-Wahnefried W, et al. Nutrition and physical activity guidelines for cancer survivors. CA Cancer J Clin. 2012;62(4):243–274.
14. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015;65(1):5–29.
15. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87–108.
16. Schmandt RE, Iglesias DA, Co NN, Lu KH. Understanding obesity and endometrial cancer risk: opportunities for prevention. Am J Obstet Gynecol. 2011;205(6):518–525.
17. Talavera F, Reynolds RK, Roberts JA, Menon KM. Insulin-like growth factor I receptors in normal and neoplastic human endometrium. Cancer Res. 1990;50(10):3019–3024.
18. Reeves GK, Pirie K, Beral V, Green J, Spencer E, Bull D. Cancer incidence and mortality in relation to body mass index in the Million Women Study: cohort study. BMJ. 2007;335(7630):1134.
19. Schouten LJ, Goldbohm RA, van den Brandt PA. Anthropometry, physical activity, and endometrial cancer risk: results from the Netherlands Cohort Study. J Natl Cancer Inst. 2004;96(21):1635–1638.
20. Zhang Y, Liu H, Yang S, Zhang J, Qian L, Chen X. Overweight, obesity and endometrial cancer risk: results from a systematic review and meta-analysis. Int J Biol Markers. 2014;29(1):e21–e29.
21. Setiawan VW, Yang HP, Pike MC, et al. Type I and II endometrial cancers: have they different risk factors? J Clin Oncol. 2013;31(20):2607–2618.
22. Howlader N, Noone AM, Krapcho M, et al. [webpage on the Internet]. SEER Cancer Statistics Review, 1975–2012, National Cancer Institute. Bethesda, MD; 2015 [updated November 18, 2015], Available from: http://seer.cancer.gov/csr/1975_2012. Accessed January 6, 2016.
23. Parker ED, Folsom AR. Intentional weight loss and incidence of obesity-related cancers: the Iowa Women’s Health Study. Int J Obes Relat Metab Disord. 2003;27(12):1447–1452.
24. Upala S, Anawin S. Bariatric surgery and risk of postoperative endometrial cancer: a systematic review and meta-analysis. Surg Obes Relat Dis. 2015;11(4):949–955.
25. Thompson HJ, McTiernan A. Weight cycling and cancer: weighing the evidence of intermittent caloric restriction and cancer risk. Cancer Prev Res (Phila). 2011;4(11):1736–1742.
26. Keum N, Greenwood DC, Lee DH, et al. Adult weight gain and adiposity-related cancers: a dose-response meta-analysis of prospective observational studies. J Natl Cancer Inst. 2015;107(2):dju428.
27. Voskuil DW, Monninkhof EM, Elias SG, Vlems FA, van Leeuwen FE; Task Force Physical Activity and Cancer. Physical activity and endometrial cancer risk, a systematic review of current evidence. Cancer Epidemiol Biomarkers Prev. 2007;16(4):639–648.
28. Cust AE, Armstrong BK, Friedenreich CM, Slimani N, Bauman A. Physical activity and endometrial cancer risk: a review of the current evidence, biologic mechanisms and the quality of physical activity assessment methods. Cancer Causes Control. 2007;18(3):243–258.
29. Du M, Kraft P, Eliassen AH, Giovannucci E, Hankinson SE, De Vivo I. Physical activity and risk of endometrial adenocarcinoma in the Nurses’ Health Study. Int J Cancer. 2014;134(11):2707–2716.
30. Patel AV, Feigelson HS, Talbot JT, et al. The role of body weight in the relationship between physical activity and endometrial cancer: results from a large cohort of US women. Int J Cancer. 2008;123(8):1877–1882.
31. Prentice RL, Thomson CA, Caan B, et al. Low-fat dietary pattern and cancer incidence in the women’s health initiative dietary modification randomized controlled trial. J Natl Cancer Inst. 2007;99(20):1534–1543.
32. Filomeno M, Bosetti C, Bidoli E, et al. Mediterranean diet and risk of endometrial cancer: a pooled analysis of three Italian case-control studies. Br J Cancer. 2015;112(11):1816–1821.
33. George SM, Ballard R, Shikany JM, Crane TE, Neuhouser ML. A prospective analysis of diet quality and endometrial cancer among 84,415 postmenopausal women in the Women’s Health Initiative. Ann Epidemiol. 2015;25(10):788–793.
34. Mulholland HG, Murray LJ, Cardwell CR, Cantwell MM. Dietary glycaemic index, glycaemic load and endometrial and ovarian cancer risk: a systematic review and meta-analysis. Br J Cancer. 2008;99(3):434–441.
35. Nagle CM, Olsen CM, Ibiebele TI, Spurdle AB, Webb PM. Glycemic index, glycemic load and endometrial cancer risk: results from the Australian National Endometrial Cancer study and an updated systematic review and meta-analysis. Eur J Nutr. 2013;52(2):705–715.
36. Bandera EV, Kushi LH, Moore DF, Gifkins DM, McCullough ML. Consumption of animal foods and endometrial cancer risk: a systematic literature review and meta-analysis. Cancer Causes Control. 2007;18(9):967–988.
37. Zhou Q, Luo M-L, Li H, Li M, Zhou J-G. Coffee consumption and risk of endometrial cancer: a dose-response meta-analysis of prospective cohort studies. Sci Rep. 2015;5:13410.
38. Zhou Q, Li H, Zhou J-G, Ma Y, Wu T, Ma H. Green tea, black tea consumption and risk of endometrial cancer: a systematic review and meta-analysis. Arch Gynecol Obstet. 2015;293(1):143–155.
39. Sun Q, Xu L, Zhou B, Wang Y, Jing Y, Wang B. Alcohol consumption and the risk of endometrial cancer: a meta-analysis. Asia Pac J Clin Nutr. 2011;20(1):125–133.
40. Inoue-Choi M, Robien K, Mariani A, Cerhan JR, Anderson KE. Sugar-sweetened beverage intake and the risk of type I and type II endometrial cancer among postmenopausal women. Cancer Epidemiol Biomarkers Prev. 2013;22(12):2384–2394.
41. Zhou B, Yang L, Sun Q, et al. Cigarette smoking and the risk of endometrial cancer: a meta-analysis. Am J Med. 2008;121(6):501 e–508 e.
42. Ward KK, Roncancio AM, Shah NR, et al. Bariatric surgery decreases the risk of uterine malignancy. Gynecol Oncol. 2014;133(1):63–66.
43. Modesitt SC, Hallowell PT, Slack-Davis JK, et al. Women at extreme risk for obesity-related carcinogenesis: baseline endometrial pathology and impact of bariatric surgery on weight, metabolic profiles and quality of life. Gynecol Oncol. 2015;138(2):238–245.
44. Kaiyrlykyzy A, Freese KE, Elishaev E, et al. Endometrial histology in severely obese bariatric surgery candidates: an exploratory analysis. Surg Obes Relat Dis. 2013;11(3):653–658.
45. Argenta P, Svendsen C, Elishaev E, et al. Hormone receptor expression patterns in the endometrium of asymptomatic morbidly obese women before and after bariatric surgery. Gynecol Oncol. 2014;133(1):78–82.
46. Linkov F, Elishaev E, Gloyeske N, et al. Bariatric surgery-induced weight loss changes immune markers in the endometrium of morbidly obese women. Surg Obes Relat Dis. 2014;10(5):921–926.
47. Collaborative Group on Epidemiological Studies on Endometrial Cancer. Endometrial cancer and oral contraceptives: an individual participant meta-analysis of 27,276 women with endometrial cancer from 36 epidemiological studies. Lancet Oncol. 2015;16(9):1061–1070.
48. Depot-medroxyprogesterone acetate (DMPA) and risk of endometrial cancer. The WHO Collaborative Study of Neoplasia and Steroid Contraceptives. Int J Cancer. 1991;49(2):186–190.
49. Felix AS, Gaudet MM, La Vecchia C, et al. Intrauterine devices and endometrial cancer risk: a pooled analysis of the Epidemiology of Endometrial Cancer Consortium. Int J Cancer. 2015;136(5):E410–E422.
50. Grady D, Gebretsadik T, Kerlikowske K, Ernster V, Petitti D. Hormone replacement therapy and endometrial cancer risk: a meta-analysis. Obstet Gynecol. 1995;85(2):304–313.
51. Anderson GL, Judd HL, Kaunitz AM, et al. Effects of estrogen plus progestin on gynecologic cancers and associated diagnostic procedures: the Women’s Health Initiative randomized trial. JAMA. 2003;290(13):1739–1748.
52. Beral V, Bull D, Reeves G; Million Women Study Collaborators. Endometrial cancer and hormone-replacement therapy in the Million Women Study. Lancet (London, England). 2005;365(9470):1543–1551.
53. Neill AS, Nagle CM, Protani MM, Obermair A, Spurdle AB, Webb PM. Aspirin, nonsteroidal anti-inflammatory drugs, paracetamol and risk of endometrial cancer: a case-control study, systematic review and meta-analysis. Int J Cancer. 2013;132(5):1146–1155.
54. Tabrizi AD, Melli MS, Foroughi M, Ghojazadeh M, Bidadi S. Antiproliferative effect of metformin on the endometrium – a clinical trial. Asian Pac J Cancer Prev. 2014;15(23):10067–10070.
55. Tan BK, Adya R, Chen J, Lehnert H, Sant Cassia LJ, Randeva HS. Metformin treatment exerts antiinvasive and antimetastatic effects in human endometrial carcinoma cells. J Clin Endocrinol Metab. 2011;96(3):808–816.
56. Tseng C-H. Metformin reduces ovarian cancer risk in Taiwanese women with type 2 diabetes mellitus. Diabetes Metab Res Rev. 2015;31(6):619–626.
57. Ko EM, Stürmer T, Hong J-L, Castillo WC, Bae-Jump V, Funk MJ. Metformin and the risk of endometrial cancer: a population-based cohort study. Gynecol Oncol. 2015;136(2):341–347.
58. Soffer D, Shi J, Chung J, et al. Metformin and breast and gynecological cancer risk among women with diabetes. BMJ Open Diabetes Res care. 2015;3(1):e000049.
59. ClinicalTrials.gov [webpage on the Internet]. An Endometrial Cancer Chemoprevention Study of Metformin; 2012 [updated July 27, 2015]. 1-1 Available from: https://clinicaltrials.gov/ct2/show/NCT01697566?term=metformin+endometrial+cancer&rank=4. Accessed December 30, 2015.
60. Wang L, Li J, Shi Z. Association between breastfeeding and endometrial cancer risk: evidence from a systematic review and meta-analysis. Nutrients. 2015;7(7):5697–5711.
61. Siegel R, DeSantis C, Virgo K, et al. Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin. 2012;62(4):220–241.
62. Mishra S, Scherer R, Snyder C, Geigle P, Berlanstein D, Topaloglu O. Exercise interventions on health-related quality of life for people with cancer during active treatment (Review). Cochrane Collab. 2012;8;CD008465.
63. Smits A, Lopes A, Bekkers R, Galaal K. Body mass index and the quality of life of endometrial cancer survivors – a systematic review and meta-analysis. Gynecol Oncol. 2015;137(1):180–187.
64. von Gruenigen VE, Waggoner SE, Frasure HE, et al. Lifestyle challenges in endometrial cancer survivorship. Obstet Gynecol. 2011;117(1):93–100.
65. Lauver D, Connolly-Nelson K, Vang P. Health-related goals in female cancer survivors after treatment. Cancer Nurs. 2007;30(1):9–15.
66. Rossi A, Moadel-Robblee A, Garber CE, et al. Physical activity for an ethnically diverse sample of endometrial cancer survivors: a needs assessment and pilot intervention. J Gynecol Oncol. 2015;26(2):141–147
67. Neff R, McCann GA, Carpenter KM, et al. Is bariatric surgery an option for women with gynecologic cancer? Examining weight loss counseling practices and training among gynecologic oncology providers. Gynecol Oncol. 2014;134(3):540–545.
68. Beavis AL, Cheema S, Holschneider CH, Duffy EL, Amneus MW. Almost half of women with endometrial cancer or hyperplasia do not know that obesity affects their cancer risk. Gynecol Oncol Rep. 2015;13:71–75.
69. Tseng JH, Long Roche K, Jernigan AM, Salani R, Bristow RE, Fader AN. Lifestyle and weight management counseling in uterine cancer survivors: a study of the uterine cancer action network. Int J Gynecol Cancer. 2015;25(7):1285–1291.
70. von Gruenigen V, Frasure H, Kavanagh MB, et al. Survivors of uterine cancer empowered by exercise and healthy diet (SUCCEED): a randomized controlled trial. Gynecol Oncol. 2012;125(3):699–704.
71. McCarroll ML, Armbruster S, Frasure HE, et al. Self-efficacy, quality of life, and weight loss in overweight/obese endometrial cancer survivors (SUCCEED): a randomized controlled trial. Gynecol Oncol. 2014;132(2):397–402.
72. McCarroll ML, Armbruster S, Pohle-Krauza RJ, et al. Feasibility of a lifestyle intervention for overweight/obese endometrial and breast cancer survivors using an interactive mobile application. Gynecol Oncol. 2015;137(3):508–515.
73. Basen-Engquist K, Carmack C, Brown J, et al. Response to an exercise intervention after endometrial cancer: differences between obese and non-obese survivors. Gynecol Oncol. 2014;133(1):48–55.
74. Nock NL, Dimitropoulos A, Rao SM, et al. Rationale and design of REWARD (revving-up exercise for sustained weight loss by altering neurological reward and drive): a randomized trial in obese endometrial cancer survivors. Contemp Clin Trials. 2014;39(2):236–245.
75. Koutoukidis DA, Knobf MT, Lanceley A. Obesity, diet, physical activity, and health-related quality of life in endometrial cancer survivors. Nutr Rev. 2015;73(6):399–408.
76. Ko EM, Walter P, Jackson A, et al. Metformin is associated with improved survival in endometrial cancer. Gynecol Oncol. 2014;132(2):438–442.
77. Nevadunsky NS, Van Arsdale A, Strickler HD, et al. Metformin use and endometrial cancer survival. Gynecol Oncol. 2014;132(1):236–240.
78. Al Hilli MM, Bakkum-Gamez JN, Mariani A, et al. The effect of diabetes and metformin on clinical outcomes is negligible in risk-adjusted endometrial cancer cohorts. Gynecol Oncol. 2016;140(2):270–276.
79. Hall C, Stone RL, Gehlot A, Zorn KK, Burnett AF. Use of metformin in obese women with type I endometrial cancer is associated with a reduced incidence of cancer recurrence. Int J Gynecol Cancer. 2016;26(2):313–317.
80. ClinicalTrials.gov [webpage on the Internet]. Paclitaxel and Carboplatin With or Without Metformin Hydrochloride in Treating Patients with Stage III, IV, or Recurrent Endometrial Cancer; 2014 [updated July 13, 2015]. Available from: https://clinicaltrials.gov/ct2/show/NCT02065687?term=endometrial+cancer+metformin&rank=5. Accessed December 30, 2015.
81. Kotsopoulos J, Baer HJ, Tworoger SS. Anthropometric measures and risk of epithelial ovarian cancer: results from the nurses’ health study. Obesity. 2010;18(8):1625–1631.
82. Collaborative Group on Epidemiological Studies of Ovarian Cancer. Ovarian cancer and body size: individual participant meta-analysis including 25,157 women with ovarian cancer from 47 epidemiological studies. PLoS Med. 2012;9(4):e1001200.
83. Zhou Y, Chlebowski R, LaMonte MJ, et al. Body mass index, physical activity, and mortality in women diagnosed with ovarian cancer: results from the Women’s Health Initiative. Gynecol Oncol. 2014;133(1):4–10.
84. Cannioto RA, Moysich KB. Epithelial ovarian cancer and recreational physical activity: a review of the epidemiological literature and implications for exercise prescription. Gynecol Oncol. 2015;137(3):559–573.
85. Zhong S, Chen L, Lv M, Ma T, Zhang X, Zhao J. Nonoccupational physical activity and risk of ovarian cancer: a meta-analysis. Tumour Biol. 2014;35(11):11065–11073.
86. Bertone ER, Rosner BA, Hunter DJ, et al. Dietary fat intake and ovarian cancer in a cohort of US women. Am J Epidemiol. 2002;156(1):22–31.
87. Crane TE, Khulpateea BR, Alberts DS, Basen-Engquist K, Thomson CA. Dietary intake and ovarian cancer risk: a systematic review. Cancer Epidemiol Biomarkers Prev. 2014;23(2):255–273.
88. Xie J, Poole EM, Terry KL, et al. A prospective cohort study of dietary indices and incidence of epithelial ovarian cancer. J Ovarian Res. 2014;7:112.
89. Chandran U, Bandera EV, Williams-King MG, et al. Healthy eating index and ovarian cancer risk. Cancer Causes Control. 2011;22(4):563–571.
90. Hu J, Hu Y, Hu Y, Zheng S. Intake of cruciferous vegetables is associated with reduced risk of ovarian cancer: a meta-analysis. Asia Pac J Clin Nutr. 2015;24(1):101–109.
91. Han B, Li X, Yu T. Cruciferous vegetables consumption and the risk of ovarian cancer: a meta-analysis of observational studies. Diagn Pathol. 2014;9:7.
92. Liu J, Tang W, Sang L, et al. Milk, yogurt, and lactose intake and ovarian cancer risk: a meta-analysis. Nutr Cancer. 2014;67(1): 68–72.
93. Jiang P, Jiang Z, Shen K, Yue Y. Fish intake and ovarian cancer risk: a meta-analysis of 15 case-control and cohort studies. PLoS One. 2014;9(4):e94601.
94. Braem MGM, Onland-Moret NC, Schouten LJ, et al. Coffee and tea consumption and the risk of ovarian cancer: a prospective cohort study and updated meta-analysis. Am J Clin Nutr. 2012;95(5):1172–1181.
95. Gosvig CF, Kjaer SK, Blaakær J, Høgdall E, Høgdall C, Jensen A. Coffee, tea, and caffeine consumption and risk of epithelial ovarian cancer and borderline ovarian tumors: results from a Danish case-control study. Acta Oncol (Madr). 2015;54(8):1144–1151.
96. Oppeneer SJ, Robien K. Tea consumption and epithelial ovarian cancer risk: a systematic review of observational studies. Nutr Cancer. 2011;63(6):817–826.
97. Cassidy A, Huang T, Rice MS, Rimm EB, Tworoger SS. Intake of dietary flavonoids and risk of epithelial ovarian cancer. Am J Clin Nutr. 2014;100(5):1344–1351.
98. Gao M, Ma W, Chen X-B, Chang Z-W, Zhang X-D, Zhang M-Z. Meta-analysis of green tea drinking and the prevalence of gynecological tumors in women. Asia Pac J Public Health. 2013;25(4 suppl):43S–48S.
99. Tasevska N, Jiao L, Cross AJ, et al. Sugars in diet and risk of cancer in the NIH-AARP Diet and Health Study. Int J Cancer. 2012;130(1):159–169.
100. Silvera SAN, Jain M, Howe GR, Miller AB, Rohan TE. Glycaemic index, glycaemic load and ovarian cancer risk: a prospective cohort study. Public Health Nutr. 2007;10(10):1076–1081.
101. King MG, Olson SH, Paddock L, et al. Sugary food and beverage consumption and epithelial ovarian cancer risk: a population-based case-control study. BMC Cancer. 2013;13:94.
102. Yan-Hong H, Jing L, Hong L, Shan-Shan H, Yan L, Ju L. Association between alcohol consumption and the risk of ovarian cancer: a meta-analysis of prospective observational studies. BMC Public Health. 2015;15:223.
103. Kelemen LE, Bandera EV, Terry KL, et al. Recent alcohol consumption and risk of incident ovarian carcinoma: a pooled analysis of 5,342 cases and 10,358 controls from the Ovarian Cancer Association Consortium. BMC Cancer. 2013;13:28.
104. Rota M, Pasquali E, Scotti L, et al. Alcohol drinking and epithelial ovarian cancer risk. A systematic review and meta-analysis. Gynecol Oncol. 2012;125(3):758–763.
105. Tworoger SS, Gertig DM, Gates MA, Hecht JL, Hankinson SE. Caffeine, alcohol, smoking, and the risk of incident epithelial ovarian cancer. Cancer. 2008;112(5):1169–1177.
106. Beral V, Gaitskell K, Hermon C, Moser K, Reeves G, Peto R. Ovarian cancer and smoking: individual participant meta-analysis including g 28,114 women with ovarian cancer from 51 epidemiological studies. Lancet Oncol. 2012;13(9):946–956.
107. Faber MT, Kjær SK, Dehlendorff C, et al. Cigarette smoking and risk of ovarian cancer: a pooled analysis of 21 case-control studies. Cancer Causes Control. 2013;24(5):989–1004.
108. Li D-P, Du C, Zhang Z-M, et al. Breastfeeding and ovarian cancer risk: a systematic review and meta-analysis of 40 epidemiological studies. Asian Pac J Cancer Prev. 2014;15(12):4829–4837.
109. Feng L-P, Chen H-L, Shen M-Y. Breastfeeding and the risk of ovarian cancer: a meta-analysis. J Midwifery Womens Health. 2014;59(4):428–437.
110. Rice MS, Murphy MA, Tworoger SS. Tubal ligation, hysterectomy and ovarian cancer: a meta-analysis. J Ovarian Res. 2012;5(1):13.
111. Walker JL, Powell CB, Chen L-M, et al. Society of Gynecologic Oncology recommendations for the prevention of ovarian cancer. Cancer. Epub 2015 Mar 27.
112. Marchetti C, De Felice F, Palaia I, et al. Risk-reducing salpingo-oophorectomy: a meta-analysis on impact on ovarian cancer risk and all cause mortality in BRCA 1 and BRCA 2 mutation carriers. BMC Womens Health. 2014;14:150.
113. Beral V, Doll R, Hermon C, Peto R, Reeves G; Collaborative Group on Epidemiological Studies of Ovarian Cancer. Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23,257 women with ovarian cancer and 87,303 controls. Lancet. 2008;371(9609):303–314.
114. Lurie G, Thompson P, McDuffie KE, Carney ME, Terada KY, Goodman MT. Association of estrogen and progestin potency of oral contraceptives with ovarian carcinoma risk. Obstet Gynecol. 2007;109(3):597–607.
115. Wilailak S, Vipupinyo C, Suraseranivong V, et al. Depot medroxyprogesterone acetate and epithelial ovarian cancer: a multicentre case-control study. BJOG. 2012;119(6):672–677.
116. Urban M, Banks E, Egger S, et al. Injectable and oral contraceptive use and cancers of the breast, cervix, ovary, and endometrium in black South African women: case-control study. PLoS Med. 2012;9(3):e1001182.
117. Depot-medroxyprogesterone acetate (DMPA) and risk of epithelial ovarian cancer. The WHO Collaborative Study of Neoplasia and Steroid Contraceptives. Int J Cancer. 1991;49(2):191–195.
118. Liang AP, Levenson AG, Layde PM, et al. Risk of breast, uterine corpus, and ovarian cancer in women receiving medroxyprogesterone injections. JAMA. 1983;249(21):2909–2912.
119. Huang Z, Gao Y, Wen W, et al. Contraceptive methods and ovarian cancer risk among Chinese women: a report from the Shanghai Women’s Health Study. Int J Cancer. 2015;137(3):607–614.
120. Dorjgochoo T, Shu X-O, Li H-L, et al. Use of oral contraceptives, intrauterine devices and tubal sterilization and cancer risk in a large prospective study, from 1996 to 2006. Int J Cancer. 2009;124(10):2442–2449.
121. Shu XO, Brinton LA, Gao YT, Yuan JM. Population-based case-control study of ovarian cancer in Shanghai. Cancer Res. 1989;49(13):3670–3674.
122. Anderson GL, Judd HL, Kaunitz AM, et al. Effects of estrogen plus progestin on gynecologic cancers and associated diagnostic procedures. JAMA. 2003;290(13):1739.
123. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women’s Health Initiative randomized controlled trial. JAMA. 2002;288(3):321–333.
124. Beral V, Gaitskell K, Hermon C, Moser K, Reeves G, Peto R. Menopausal hormone use and ovarian cancer risk: individual participant meta-analysis of 52 epidemiological studies. Lancet. 2015;385(9980):1835–1842.
125. Danforth KN, Tworoger SS, Hecht JL, Rosner BA, Colditz GA, Hankinson SE. A prospective study of postmenopausal hormone use and ovarian cancer risk. Br J Cancer. 2006;96(1):151–156.
126. Lavie O, Pinchev M, Rennert HS, Segev Y, Rennert G. The effect of statins on risk and survival of gynecological malignancies. Gynecol Oncol. 2013;130(3):615–619.
127. Robinson E, Nandi M, Wilkinson LL, Arrowsmith DM, Curtis ADM, Richardson A. Preclinical evaluation of statins as a treatment for ovarian cancer. Gynecol Oncol. 2013;129(2):417–424.
128. Pinheiro SP, Tworoger SS, Cramer DW, Rosner BA, Hankinson SE. Use of nonsteroidal antiinflammatory agents and incidence of ovarian cancer in 2 large prospective cohorts. Am J Epidemiol. 2009;169(11):1378–1387.
129. Cook NR, Lee I-M, Gaziano JM, et al. Low-dose aspirin in the primary prevention of cancer: the Women’s Health Study: a randomized controlled trial. JAMA. 2005;294(1):47–55.
130. Trabert B, Ness RB, Lo-Ciganic W-H, et al. Aspirin, nonaspirin nonsteroidal anti-inflammatory drug, and acetaminophen use and risk of invasive epithelial ovarian cancer: a pooled analysis in the Ovarian Cancer Association Consortium. J Natl Cancer Inst. 2014;106(2): djt431.
131. Ni X, Ma J, Zhao Y, Wang Y, Wang S. Meta-analysis on the association between non-steroidal anti-inflammatory drug use and ovarian cancer. Br J Clin Pharmacol. 2013;75(1):26–35.
132. Baandrup L, Faber MT, Christensen J, et al. Nonsteroidal anti-inflammatory drugs and risk of ovarian cancer: systematic review and meta-analysis of observational studies. Acta Obstet Gynecol Scand. 2013;92(3):245–255.
133. Murphy MA, Trabert B, Yang HP, et al. Non-steroidal anti-inflammatory drug use and ovarian cancer risk: findings from the NIH-AARP Diet and Health Study and systematic review. Cancer Causes Control. 2012;23(11):1839–1852.
134. Bodmer M, Becker C, Meier C, Jick SS, Meier CR. Use of metformin and the risk of ovarian cancer: a case-control analysis. Gynecol Oncol. 2011;123(2):200–204.
135. Shah MM, Erickson BK, Matin T, et al. Diabetes mellitus and ovarian cancer: more complex than just increasing risk. Gynecol Oncol. 2014;135(2):273–277.
136. Nagle CM, Dixon SC, Jensen A, et al. Obesity and survival among women with ovarian cancer: results from the Ovarian Cancer Association Consortium. Br J Cancer. 2015;113(5):817–826.
137. Smits A, Smits E, Lopes A, et al. Body mass index, physical activity and quality of life of ovarian cancer survivors: time to get moving? Gynecol Oncol. 2015;139(1):148–154.
138. von Gruenigen VE, Frasure HE, Jenison EL, Hopkins MP, Gil KM. Longitudinal assessment of quality of life and lifestyle in newly diagnosed ovarian cancer patients: the roles of surgery and chemotherapy. Gynecol Oncol. 2006;103(1):120–126.
139. Mizrahi D, Naumann F, Broderick C, Samara J, Ryan M, Friedlander M. Quantifying physical activity and the associated barriers for women with ovarian cancer. Int J Gynecol Cancer. 2015;25(4):577–583.
140. Mizrahi D, Broderick C, Friedlander M, et al. An exercise intervention during chemotherapy for women with recurrent ovarian cancer: a feasibility study. Int J Gynecol Cancer. 2015;25(6):985–992.
141. Stevinson C, Faught W, Steed H, et al. Associations between physical activity and quality of life in ovarian cancer survivors. Gynecol Oncol. 2007;106(1):244–250.
142. Beesley VL, Price MA, Butow PN, Green AC, Olsen CM, Webb PM. Physical activity in women with ovarian cancer and its association with decreased distress and improved quality of life. Psychooncology. 2011;20(11):1161–1169.
143. Hwang K-H, Cho O-H, Yoo Y-S. The effect of comprehensive care program for ovarian cancer survivors. Clin Nurs Res. Epub 2014 Nov 26.
144. Moonsammy SH, Guglietti CL, Santa Mina D, et al. A pilot study of an exercise & cognitive behavioral therapy intervention for epithelial ovarian cancer patients. J Ovarian Res. 2013;6(1):21.
145. von Gruenigen VE, Frasure HE, Kavanagh MB, Lerner E, Waggoner SE, Courneya KS. Feasibility of a lifestyle intervention for ovarian cancer patients receiving adjuvant chemotherapy. Gynecol Oncol. 2011;122(2):328–333.
146. Newton MJ, Hayes SC, Janda M, et al. Safety, feasibility and effects of an individualised walking intervention for women undergoing chemotherapy for ovarian cancer: a pilot study. BMC Cancer. 2011;11:389.
147. Paxton RJ, Garcia-Prieto C, Berglund M, et al. A randomized parallel-group dietary study for stages II-IV ovarian cancer survivors. Gynecol Oncol. 2012;124(3):410–416.
148. Thomson CA, E Crane T, Wertheim BC, et al. Diet quality and survival after ovarian cancer: results from the Women’s Health Initiative. J Natl Cancer Inst. 2014;106(11): dju314.
149. ClinicalTrials.gov [webpage on the Internet]. Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer; 2008 [updated July 13, 2014]. Available from: https://clinicaltrials.gov/ct2/show/NCT00719303?term=%22ovarian+cancer%22+diet&recr=Open&rank=3. Accessed September 25, 2015.
150. Li D, Ding C, Qiu L. Postoperative hormone replacement therapy for epithelial ovarian cancer patients: a systematic review and meta-analysis. Gynecol Oncol. 2015;139(2):355–362.
151. Eeles RA, Morden JP, Gore M, et al. Adjuvant hormone therapy may improve survival in epithelial ovarian cancer: results of the AHT randomized trial. J Clin Oncol. 2015;33(35):4138–4144.
152. Neff R, Havrilesky LJ, Chino J, O’Malley DM, Cohn DE. Bariatric surgery as a means to decrease mortality in women with type I endometrial cancer – an intriguing option in a population at risk for dying of complications of metabolic syndrome. Gynecol Oncol. 2015;138(3):597–602.
153. ClinicalTrials.gov [webpage on the Internet]. Feasibility Study: Therapeutic Targeting of Stress Factors in Ovarian Cancer Patients; 2012 [updated November 3, 2015]. Available from: https://clinicaltrials.gov/show/NCT01504126. Accessed January 6, 2016.
154. Fallowfield L, Fleissig A, Barrett J, et al. Awareness of ovarian cancer risk factors, beliefs and attitudes towards screening: baseline survey of 21,715 women participating in the UK Collaborative Trial of Ovarian Cancer Screening. Br J Cancer. 2010;103(4):454–461.
155. Bui KT, Wakefield CE, Kasparian NA, Tyler J, Abbott J, Tucker K. Oral contraceptive use in women at increased risk of breast/ovarian cancer: knowledge and attitudes. Psychooncology. 2013;22(1):228–232.
156. Donnelly CM, Blaney JM, Lowe-Strong A, et al. A randomised controlled trial testing the feasibility and efficacy of a physical activity behavioural change intervention in managing fatigue with gynaecological cancer survivors. Gynecol Oncol. 2011;122(3):618–624.